ECM
ANIP icon

Endurant Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Endurant Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-59,900
Closed -$3.14M – 76
2017
Q3 		$3.14M Buy
59,900
+44,300
+284% +$2.11M 0.95% 35
2017
Q2 		$730K Buy
+15,600
New +$753K 0.21% 77
2016
Q4 		– Sell
-4,600
Closed -$305K – 75
2016
Q3 		$305K Buy
+4,600
New +$288K 0.11% 90

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Endurant Capital Management's ANIP Position: Q4 2017 in Review

Endurant Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2017, closing a stake of 59,900 shares — an estimated $3.14M sold.

Endurant Capital Management first reported a position in ANIP in Q3 2016 and held it in 3 quarters. The position peaked at $3.14M in Q3 2017. 163 funds tracked by Wall St. Rank hold ANIP as of Q4 2017.

  • Endurant Capital Management reported no remaining ANI Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Endurant Capital Management sold 59,900 ANI Pharmaceuticals shares in Q4 2017, an estimated $3.14M.
  • Endurant Capital Management first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Endurant Capital Management's ANI Pharmaceuticals position peaked at $3.14M in Q3 2017.
  • 163 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2017.

Based on Endurant Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.